Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Max PetersMarco van Vulpen

Abstract

Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (> 90 days) genitourinary (GU) toxicity are presented here. Dosimetry on intraoperative ultrasound (US) of 20 FS and 28 TS patients was compared. The prostate, bladder, urethra and bulbomembranous (BM) urethra were delineated. Toxicity was assessed using the CTCAE version 4.0. Dose constraints to reduce toxicity in TS patients were evaluated with receiver operating characteristic (ROC) analysis. FS I-125 BT significantly reduces bladder and urethral dose compared to TS. Grade 3 GU toxicity occurred once in the FS group. For TS patients late severe (⩾ grade 3) GU toxicity was frequent (38% in the total 61 patients and 56% in the 27 analyzed patients). TS patients with ⩾ grade 3 GU toxicity showed higher bladder D2 cc than TS patients without toxicity (median 43 Gy) (p = 0.02). The urethral V100 was significantly higher ...Continue Reading

References

Mar 2, 2002·International Journal of Radiation Oncology, Biology, Physics·Juanita CrookMelania Pintilie
Mar 2, 2002·International Journal of Radiation Oncology, Biology, Physics·Gregory S MerrickJonathan H Lief
Sep 6, 2003·International Journal of Radiation Oncology, Biology, Physics·Hoon K LeeDeborah A Kuban
Jul 28, 2004·International Journal of Radiation Oncology, Biology, Physics·Steven J BuskirkTodd C Igel
Jul 28, 2004·International Journal of Radiation Oncology, Biology, Physics·Libni EapenSimone Dahrouge
Mar 7, 2006·The Journal of Urology·Gregory S MerrickEdward Adamovich
Feb 27, 2007·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Carl SalembierUNKNOWN GEC ESTRO PROBATE Group
Nov 28, 2007·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Marcel J SteggerdaLuc M F Moonen
Oct 1, 2008·International Journal of Radiation Oncology, Biology, Physics·Elantholi P SaibishkumarJuanita Crook
Oct 28, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Marinus A MoerlandJan J Battermann
Jul 9, 2009·BJU International·Masaki KimuraThomas J Polascik
Dec 17, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Clare AndersonPeter J Hoskin
Jul 8, 2010·International Journal of Radiation Oncology, Biology, Physics·Ellen M A RoeloffzenMarco van Vulpen
Dec 15, 2010·International Journal of Radiation Oncology, Biology, Physics·Véronique BeckendorfPierre Bey
Jan 24, 2012·Brachytherapy·Brian J DavisUNKNOWN American Brachytherapy Society
Jul 31, 2012·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·James J EarleyRobert W Laing
Aug 21, 2013·Critical Reviews in Oncology/hematology·Filippo AlongiBarbara Alicja Jereczek-Fossa
Jan 1, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Hiroshi SasakiShin Egawa
Jul 8, 2014·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Max PetersMarco van Vulpen

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.